Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $48.0600 (-1.62%) ($48.0600 - $48.0600) on Fri. Feb. 12, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.35% (three month average) | RSI | 46 | Latest Price | $48.0600(-1.62%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -2.4% a day on average for past five trading days. | Weekly Trend | TGTX advances 1.3% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(67%) ARKG(63%) ARKK(59%) IBB(58%) IWO(58%) | Factors Impacting TGTX price | TGTX will decline at least -3.175% in a week (0% probabilities). VIXM(-41%) VXX(-36%) UUP(-19%) UNG(-3%) TLT(-1%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.175% (StdDev 6.35%) | Hourly BBV | -2.1 () | Intraday Trend | 0% | | | |
|
Resistance Level | $49.45 | 5 Day Moving Average | $50.01(-3.9%) | 10 Day Moving Average | $49.88(-3.65%) | 20 Day Moving Average | $49.45(-2.81%) | To recent high | -12.2% | To recent low | 76.8% | Market Cap | $6.087b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |